Literature DB >> 21048799

Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.

Cristina Sampaio, Joaquim J Ferreira.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21048799     DOI： 10.1038/nrneurol.2010.158

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

Authors:  O Rascol; D J Brooks; A D Korczyn; P P De Deyn; C E Clarke; A E Lang
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

2.  Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.

Authors:  M M Mouradian; I J Heuser; F Baronti; T N Chase
Journal:  Ann Neurol       Date:  1990-01       Impact factor: 10.422

3.  Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

Authors:  G Block; C Liss; S Reines; J Irr; D Nibbelink
Journal:  Eur Neurol       Date:  1997       Impact factor: 1.710

4.  Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.

Authors:  Fabrizio Stocchi; Olivier Rascol; Karl Kieburtz; Werner Poewe; Joseph Jankovic; Eduardo Tolosa; Paulo Barone; Anthony E Lang; C Warren Olanow
Journal:  Ann Neurol       Date:  2010-07       Impact factor: 10.422

5.  Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.

Authors:  Lance A Smith; Michael J Jackson; Ghassan Al-Barghouthy; Sarah Rose; Mikko Kuoppamaki; Warren Olanow; Peter Jenner
Journal:  Mov Disord       Date:  2005-03       Impact factor: 10.338

6.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

Authors: 
Journal:  JAMA       Date:  2000-10-18       Impact factor: 56.272

7.  Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients.

Authors:  E Dupont; A Andersen; J Boas; E Boisen; R Borgmann; A C Helgetveit; M O Kjaer; T N Kristensen; B Mikkelsen; H Pakkenberg; J Presthus; R Stien; J Worm-Petersen; D Buch
Journal:  Acta Neurol Scand       Date:  1996-01       Impact factor: 3.209

8.  Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.

Authors:  Mikko Kuoppamäki; Kirsi Korpela; Reijo Marttila; Valtteri Kaasinen; Päivi Hartikainen; Jukka Lyytinen; Seppo Kaakkola; Jutta Hänninen; Eliisa Löyttyniemi; Marita Kailajärvi; Päivi Ruokoniemi; Juha Ellmén
Journal:  Eur J Clin Pharmacol       Date:  2009-02-20       Impact factor: 2.953

9.  The control of firing pattern in nigral dopamine neurons: single spike firing.

Authors:  A A Grace; B S Bunney
Journal:  J Neurosci       Date:  1984-11       Impact factor: 6.167

10.  Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.

Authors:  Helena Heikkinen; Anu Varhe; Tarmo Laine; Jaakko Puttonen; Marjo Kela; Seppo Kaakkola; Kari Reinikainen
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.